Deborah J. Cook, MD, MSc(Epid); Gordon H. Guyatt, MD, MSc(Epid)
Note: Dr. Cook is a Career Scientist of the Ontario Ministry of Health.
Current Author Addresses: Drs. Cook and Guyatt: Departments of Medicine and Clinical Epidemiology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
Cook DJ, Guyatt GH. Interpreting, Integrating, and Individualizing Evidence about the Prevention of Diabetic Nephropathy. Ann Intern Med. 1999;131:707-708. doi: 10.7326/0003-4819-131-9-199911020-00013
Download citation file:
Published: Ann Intern Med. 1999;131(9):707-708.
Policy-relevant research for the care of patients with diabetes mellitus is in high demand, given the prevalence, morbidity, and costs associated with this condition. Randomized trials, meta-analyses, and economic studies have evaluated myriad management strategies directed at the diagnosis, prevention, and treatment of the macrovascular and microvascular sequelae of diabetes. Accordingly, diabetes mellitus is an ideal condition for evidence-based disease management (1, 2).
A decision analysis reported in this issue focuses on prevention of diabetic nephropathy . Golan and colleagues address this question: In patients with newly diagnosed type 2 diabetes mellitus, what is the relative impact on quality-adjusted life expectancy and costs associated with 1) treating all patients with angiotensin-converting enzyme [ACE] inhibitors, 2) screening for microalbuminuria and treating with ACE inhibitors when it develops, or 3) screening and treating only for gross proteinuria?
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Nephrology, Diabetes, Diabetic Nephropathy.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only